Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 13/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 12/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432155 | 0.94 | ITGB1 (0.52) | ITGA4ITGB1METPDCD1CD274 | |
| SCHEMBL2434330 | 0.92 | ITGB1 (0.64) | ITGA4ITGB1METS1PR1S1PR3 | |
| SCHEMBL2434329 | 0.92 | ITGB1 (0.64) | ITGA4ITGB1METS1PR1S1PR3 | |
| SCHEMBL2437992 | 0.90 | ITGB1 (0.56) | ITGA4ITGB1METPDCD1CD274 | |
| SCHEMBL2437991 | 0.90 | ITGB1 (0.56) | ITGA4ITGB1METPDCD1CD274 | |
| SCHEMBL2436543 | 0.87 | ITGB1 (0.63) | ITGA4ITGB1METS1PR1S1PR3 | |
| SCHEMBL2436546 | 0.87 | ITGB1 (0.63) | ITGA4ITGB1METS1PR1S1PR3 | |
| SCHEMBL2432628 | 0.87 | ITGA4 (0.39) | ITGA4ITGB1METS1PR1S1PR3 | |
| SCHEMBL2429803 | 0.85 | ITGB1 (0.64) | ITGA4ITGB1METS1PR1S1PR3 | |
| SCHEMBL2429801 | 0.85 | ITGB1 (0.64) | ITGA4ITGB1METS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGA4 4/4885ITGB1 5/4885MET 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.